RT期刊文章SR电子T1葡萄糖胺使用与肺癌风险的关系：来自全国范围内的肺癌症课程JF欧洲呼吸期刊Jo EUR Respir J FD欧洲呼吸学会SP 2101399 DO 10.1183 / 13993003.01399-2021 A1 Li，Guowei A1 Zhang188bet官网地址, Xuhui A1 Liu, Yingxin A1 Zhang, Junguo A1 Li, Likang A1 Huang, Xin A1 Thabane, Lehana A1 Lip, Gregory Y.H. YR 2021 UL //www.qdcxjkg.com/content/early/2021/07/21/13993003.01399-2021.abstract AB Background Research on glucosamine shows anti-inflammatory and anti-cancer benefits with a minimal adverse effects. We aimed to explore the relationship between use of glucosamine and risk of lung cancer and lung cancer mortality based on data from the large-scale nationwide prospective UK Biobank cohort study.Methods Participants were enrolled between the year 2006 and 2010 and followed up to 2020. Cox proportion hazards model were used to assess the relationship between glucosamine use and risk of lung cancer and lung cancer mortality. Subgroup analyses and sensitivity analyses were performed to explore the potential effect modifications and the robustness of main findings.Results A total of 439,393 participants (mean age: 56 years; 53% females) with a mean follow-up of 11 years were included for analyses. There were 82,603 (18.80%) participants reporting regular use of glucosamine at baseline. During follow-up, there were 1,971 (0.45%) lung cancer events documented. Glucosamine use was significantly associated with a decreased risk of lung cancer (hazard ratio=0.84, 95% CI: 0.75–0.92, p<0.001) and lung cancer mortality (hazard ratio=0.88, 95% CI: 0.81–0.96, p=0.002) in fully-adjusted models. A stronger association between glucosamine use and decreased lung cancer risk was observed in participants with a family history of lung cancer when compared to those without a family history.Conclusion Regular use of glucosamine was significantly related with decreased risk of lung cancer and lung cancer mortality, based on data from this nationwide prospective cohort study.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. li has nothing to disclose.Conflict of interest: Dr. Zhang has nothing to disclose.Conflict of interest: Dr. Liu has nothing to disclose.Conflict of interest: Dr. Zhang has nothing to disclose.Conflict of interest: Dr. Li has nothing to disclose.Conflict of interest: Dr. Huang has nothing to disclose.Conflict of interest: Dr. Thabane has nothing to disclose.Conflict of interest: Dr. Lip reports other from Novartis, Bayer/Janssen, Biotronik, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Verseon, and Daiichi-Sankyo, other from Medtronic, Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo, outside the submitted work; .